Stem cell biomarker predicts leukemia patients’ response to chemo – FierceBiotech
FierceBiotech |
Stem cell biomarker predicts leukemia patients' response to chemo
FierceBiotech The new biomarker, dubbed LSC17, is derived from leukemia stem cells. These cells promote cancer development and can elude chemotherapy, lying dormant and causing relapse even in patients who are in remission after therapy. LSC17 could become a … New stem cell-based gene test predicts patient risk in acute myeloid leukemia Signature of 17 Genes Could Predict Prognosis in AML Patients Cancer vaccine prolongs remission in leukemia patients in trial |
